Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 19/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045371 | 0.69 | ITGB3 (0.48) | ITGB3ITGAVITGA2B | |
| SCHEMBL3048532 | 0.69 | ITGB3 (0.44) | ITGB3ITGAVITGA2B | |
| SCHEMBL3051176 | 0.67 | ITGB3 (0.43) | ITGB3ITGAVITGA2B | |
| SCHEMBL3048321 | 0.66 | ITGB3 (0.41) | ITGB3ITGAVITGA2B | |
| SCHEMBL3051444 | 0.65 | ITGB3 (0.39) | ITGB3ITGAVITGA2B | |
| SCHEMBL6763742 | 0.59 | TBXAS1 (0.51) | ITGB3ITGAVITGA2B | |
| SCHEMBL27697367 | 0.59 | FFAR4 (0.58) | FFAR4FFAR1CACNA1CSCN5A | |
| SCHEMBL17883022 | 0.56 | FFAR4 (0.67) | FFAR4FFAR1 | |
| SCHEMBL30350236 | 0.56 | FFAR4 (0.69) | FFAR4FFAR1 | |
| SCHEMBL17882910 | 0.56 | FFAR4 (0.69) | FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645736-B2 | injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid | MERCK PATENT GMBH (DE) | 2010-01-12 | — | — | US | disclosed |
| US-20060287225-A1 | Integrin inhibitors for the treatment of eye diseases | SCRIPPS RESEARCH INSTITUTE, THE | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287225-A1 | Integrin inhibitors for the treatment of eye diseases | ITGA5, ITGAV, ITGB5 | FFAR4 3404/4885FFAR1 3815/4885CACNA1C 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.